RxDoctor Payments Data

Eric Davidson, MD

Cardiovascular Disease · Framingham, MANPI 1669437513

Payments from drug & device makers

$2,202in general payments, 2019–2025

Across 96 payments — averaging $22.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$334
  • Novartis$287
  • Amgen$241
  • AstraZeneca$174
  • Pfizer$124
  • Esperion Therapeutics, Inc.$109
  • plus $932 from 19 others

What the payments were for

  • Food & beverage$2,202100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,202 in reported general payments places this provider in the 50th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$320,830
Medicare patients
1,460
Services billed
3,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban441$530,256
EntrestoSacubitril/Valsartan169$184,874
Repatha SureclickEvolocumab61$75,377
XareltoRivaroxaban56$70,514
JardianceEmpagliflozin60$59,505
Praluent PenAlirocumab80$57,901
VascepaIcosapent Ethyl51$35,069
FarxigaDapagliflozin Propanediol16$12,690
Metoprolol Succinate627$12,481
Icosapent Ethyl36$9,235
Atorvastatin Calcium589$9,062
Dofetilide27$8,855
Ezetimibe134$6,790
Eplerenone58$4,899
NexletolBempedoic Acid11$4,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$124$530,256441 claims
NovartisEntresto$287$184,874169 claims
Johnson & JohnsonXarelto$334$70,51456 claims
Boehringer IngelheimJardiance$62$59,50560 claims
AstraZenecaFarxiga$174$12,69016 claims
Esperion Therapeutics, Inc.Nexletol$109$4,48411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Framingham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →